Gland Pharma Ltd
Gland Pharma Ltd Share Price Today: Live Updates & Key Insights
Get insights on Gland Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Gland Pharma Ltd Share Price Chart
GLAND at 11 Aug 2026 02:15 PM Pharmaceuticals
2881.90 +214.60(+8.05%)
Lowest Today 2808.00
Highest Today 2988.40
Today's Open 2845.50
Prev. Close 2667.30
52 Week High 2988.40
52 Week Low 1277.80
Gland Pharma Ltd Fundamentals
Traded Volume: 76,21,506
Market Cap(Cr): 47,541.74
Avg Traded Price 2894.95
1 Year return 48.84%
Upper Circuit 2,988.4
Lower Circuit 2,808
P/E TTM 42.00
P/B Ratio 4.243
Traded Value(Cr) 219644.18
EPS TTM 68.426
Book value/Share 628.670
Dividend Yield 1Y 1.33%
Gland Pharma Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Gland Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Gland Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +11.74%
1M +16.23%
3M +50.17%
1Y +48.84%
YTD +55.52%
Gland Pharma Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Gland Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 7.21L
Day Before Yesterday 3.18L
1W Avg 5.22L
1M Avg 4.54L
3M Avg 7.24L
Gland Pharma Ltd Technical Details
Gland Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 2623
Support 2 2579
Support 3 2548
Pivot Point : 2654
Resistance 1 2698
Resistance 2 2729
Resistance 3 2773
Gland Pharma Ltd Corporate Actions
Gland Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Gland Pharma Ltd’s capital allocation strategies.
All
Ex-Date 11-Aug-2026 Type D Description 20.00/share@2000.00% Record Date 11-Aug-2026 Ratio 2000.00
Ex-Date 14-Aug-2025 Type D Description 18.00/share@1800.00% Record Date 14-Aug-2025 Ratio 1800.00
Ex-Date 16-Aug-2024 Type D Description 20.00/share@2000.00% Record Date 16-Aug-2024 Ratio 2000.00
Dividends
Announcement Date 11-Aug-2026 Ex Dividend Date 11-Aug-2026 Dividend(%) 2000
Announcement Date 14-Aug-2025 Ex Dividend Date 14-Aug-2025 Dividend(%) 1800
Announcement Date 16-Aug-2024 Ex Dividend Date 16-Aug-2024 Dividend(%) 2000
Bonus
No Bonus has been declared by GLAND
Splits
No Split has been declared by GLAND
Others
Rights No Rights has been declared by GLAND
Gland Pharma Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Gland Pharma Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Gland Pharma Ltd's relative performance and valuation against major competitors.
Stock Name Glenmark Pharmaceuticals Ltd ₹2275.00 (+1.05%) M. Cap (Cr) 642.01 1 Yr Return (%) +11.01% P/E (TTM) 35.70 PB Ratio 6.11
Stock Name Abbott India Ltd ₹27810.00 (+1.00%) M. Cap (Cr) 590.96 1 Yr Return (%) -15.68% P/E (TTM) 38.04 PB Ratio 12.37
Stock Name Anthem Biosciences Ltd ₹889.45 (+4.27%) M. Cap (Cr) 500.95 1 Yr Return (%) NaN% P/E (TTM) 86.94 PB Ratio 16.46
Stock Name Gland Pharma Ltd ₹2881.90 (+8.05%) M. Cap (Cr) 475.42 1 Yr Return (%) +48.84% P/E (TTM) 42.15 PB Ratio 4.59
Stock Name Ajanta Pharma Ltd ₹3516.10 (+0.28%) M. Cap (Cr) 439.37 1 Yr Return (%) +32.72% P/E (TTM) 38.70 PB Ratio 9.70
Stock Name Glaxosmithkline Pharmaceuticals Ltd ₹2610.00 (+0.35%) M. Cap (Cr) 442.15 1 Yr Return (%) -2.87% P/E (TTM) 41.40 PB Ratio 19.50
Stock Name Ipca Laboratories Ltd ₹1736.70 (+3.02%) M. Cap (Cr) 440.61 1 Yr Return (%) +29.92% P/E (TTM) 38.55 PB Ratio 5.46
Gland Pharma Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Gland Pharma Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 1135.23 Mar 2025 1073.67 Mar 2024 1135.97 Mar 2023 367.89 Mar 2022 791.29
PARTICULARS Investing Activities Mar 2026 -95.56 Mar 2025 1578.20 Mar 2024 -2923.92 Mar 2023 1208.22 Mar 2022 -1010.23
PARTICULARS Financing Activities Mar 2026 -316.18 Mar 2025 -339.54 Mar 2024 -7.40 Mar 2023 14.92 Mar 2022 34.90
PARTICULARS Net Cash Flow Mar 2026 745.02 Mar 2025 2316.42 Mar 2024 -1789.01 Mar 2023 1594.04 Mar 2022 -180.73
Gland Pharma Ltd Shareholding Pattern
This shows the ownership breakdown of Gland Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 51.77%
Public 9.06%
Other Institutions 2.21%
FII 8.74%
Mutual Funds 28.23%
About Gland Pharma Ltd
Gland Pharma Limited was incorporated as `Gland Pharma Private Limited', a Private limited company on March 20, 1978 with the Registrar of Companies, Andhra Pradesh. Subsequently, name of the Company was changed to `Gland Pharma Limited' and a fresh Certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies at Hyderabad. The Company is primarily engaged in manufacturing injectable formulations.Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, including the United States, Europe, Canada, Australia, and India. Primarily functioning, company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems.Over the years, the company has made substantial investments in the companies manufacturing infrastructure to support the product portfolio needs and reach. The company has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 42 production lines and three API facilities. The companies API facilities provide with in-house manufacturing capabilities for critical APIs, enabling the company to control costs and quality and mitigate supply chain related risks around the key products. The companies capabilities as a vertically integrated company include internal research and development (R&D) expertise, robust manufacturing capabilities, a strict quality assurance system, extensive regulatory experience and established marketing and distribution relationships.As of March 31, 2020, the company along with partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products. Out of these 265 ANDA filings, 100 represent ANDAs owned by the company, of which 63 ANDA filings are approved and 37 are pending approval. As of the same date, the company along with partners had a total of 1,415 product registrations, comprising 368 product registrations in the United States, Europe, Canada and Australia, 54 in India and 993 in the Rest of the world. The company also has a consistent regulatory compliance track record and all the facilities are approved by the USFDA from whom the company have had no warning letters since the inception of each facility. Other key regulatory agencies for which certain of our facilities have approvals include MHRA (UK), TGA (Australia), ANVISA (Brazil), AGES (Austria) and BGV Hamburg (Germany).During the year 2020-21, the Company has incorporated `Gland Pharma International Pte. Ltd., a Wholly-owned Subsidiary in Singapore. It has incurred capital expenditure of Rs. 2,287.76 million at its manufacturing facilities at Dundigal, Pashamylaram, VSEZ and Pharmacity. It has issued and allotted 8,333,333 fully paid-up equity shares in the Initial Public Offer during November, 2020.During FY 2022, the Company launched 47 product SKUs of 28 molecules like Micafungin, Ziprasidone, Bivalirudin RTU and Olapatadine Ophthalmic (OTC). As of March 31, 2022, it along with the partners had 284 ANDA filings in the US, of which 234 were approved and 50 were pending approval. Out of these, 115 were owned by the Company with 85 approvals and 30 pending for approval. It had manufacturing capacity for finished formulations of approximately 767 million units per annum. It filed 21 ANDAs, 5 DMFs and received 32 ANDA approvals. It signed an agreement to supply upto 252 million doses of RDIF's Sputnik V COVID-19 vaccine. It purchased assets of Vitane Biologics, Hyderabad based biopharmaceutical company.On 27th April, 2023, Gland Pharma International Pte. Ltd., Wholly Owned Subsidiary of the Company acquired Phixen SAS and 3 holding companies in Cenexi for a purchase consideration costing Euro 114,259,004.44 and repaid a loan of Euro 79,457,194.11 on behalf of the Sellers through Share Purchase Agreement dated 6th January, 2023 and as a result, Phixen SAS and the Cenexi Holding Entities became the Wholly Owned step-down Subsidiaries of the Company, which in turn resulted in indirect acquisition of 7 subsidiaries of Cenexi, a) Cenexi SAS, (b) Cenexi Services SAS, (c) Cenexi HSC SAS, (d) Cenexi 2 SASU, (e) Cenexi 3 SASU, (f) Cenexi Laboratories Thissen SA and (g) Phineximmo SA. 'Dexrazoxane' the first product was launched in China during the year 2023.The Company launched Eribulin as its first major complex product in May, 2024. The Company commissioned a new high-capacity ampoule line, adding an annual capacity of 40 to 50 Million units at Fontenay, France in FY 2025.The Company expanded with the launch of 31 molecules in the U.S. including Argatroban, Acetazolamide, Doxycycline, Daptomycin-RTU, Sumatriptan, Dalbavancin & Colistimethate-Lyo in 2026
Chairman & Independent Directo
Yiu Kwan Stanley Lau
Registered office Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043
FAX :91-40-30510999
Background
Incorporation Year 1978
Face Value ₹1.00
Market Lot 1
FAQs on Gland Pharma Ltd
How to buy Gland Pharma Ltd shares?
To buy Gland Pharma Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Gland Pharma Ltd?
The company has a market capitalization of ₹47,541.74.
What is the PE & PB ratio of Gland Pharma Ltd?
PE is 42 and PB is 4.243.
What is the Gland Pharma Ltd dividend for 2025–26?
For the 2025–26 financial year, Gland Pharma Ltd declared a final dividend of 1.33% per share.